

| 货号 | PX-P4110 |
|---|---|
| 品牌 | ProteoGenix |
| 描述 |
Recombinant Human CD223/LAG3 Protein, C-His (PX-P4110) expressed in Mammalian Cells, Purity: >90% as determined by SDS-PAGE..
Highlights
|
| 表达系统 | Mammalian Cells |
| Accession号 | P18627 |
| 蛋白长度 | Met1-Leu450 |
| 应用 | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| 种属 | Homo sapiens (Human) |
| 性质 | Recombinant |
| 内毒素水平 | Please contact with the lab for this information. |
| 纯度 | >90% as determined by SDS-PAGE. |
| 预测分子量 | 49.64 kDa |
| 状态 | Lyophilized |
| 保存溶液 | Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 重悬 | Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details. |
| 运输 | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 别名 | FDC, LAG3, Lymphocyte activation gene 3 protein, CD223, sLAG-3, LAG-3 |
| 背景 | Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag). 1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648 2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082 3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750 4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185 5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966 6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841 7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469 8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152 10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708 |
| Note | For research use only. |

24小时产品查询

扫一扫关注我们

专属渠道经理